Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from phase I/II-study in renal cell carcinoma


Wednesday, 21 May 2014 07:44am EDT 

Immunicum AB:Reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell carcinoma.Says preliminary INTUVAX-data now also shows a partial regression of all metastases in two patients who received add-on therapy with tyrosine kinase inhibitors after INTUVAX-treatment.Says these findings suggest that combination treatment with INTUVAX and certain tyrosine kinase inhibitors can have a synergistic antitumor effect.Data from phase I/II-study in metastatic renal cell carcinoma shows a median survival for patients with poor prognosis (five patients) currently at 13 months compared to the expected median survival of 8-9 months for patients treated with tyrosine kinase inhibitors.One patient was excluded from the survival study since the patient in question in retrospect did not show any renal cell carcinoma metastases.Of the 11 remaining study patients with verified metastatic renal cancer, eight patients are still alive.